Welcome to our dedicated page for Citius Pharmaceuticals SEC filings (Ticker: CTXR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Citius Pharmaceuticals, Inc. (Nasdaq: CTXR) SEC filings page on Stock Titan provides access to the company’s official regulatory disclosures as filed with the U.S. Securities and Exchange Commission. As a Nevada-incorporated biopharmaceutical issuer (Commission File Number 001-38174), Citius Pharmaceuticals reports material events, financing transactions, and other corporate developments through forms such as Form 8-K and registration statements on Form S-3.
In its recent Form 8-K filings, Citius Pharmaceuticals has described securities purchase agreements for registered direct offerings of common stock, pre-funded warrants and common warrants, including details on exercise prices, terms, placement agent arrangements and intended use of proceeds. The company states that net proceeds are expected to support the commercial launch of LYMPHIR, milestone and regulatory payments, development initiatives for its product candidates, and general corporate purposes.
Other 8-K filings referenced by the company include notices of compliance with Nasdaq Listing Rule 5550(a)(2) regarding the minimum bid price requirement, as well as disclosures about corporate presentations and earnings press releases furnished under Regulation FD and Item 2.02. Together, these filings offer insight into CTXR’s capital strategy, listing status and communication practices with investors.
Through Stock Titan, users can review CTXR’s current and historical SEC documents, including registration statements that underpin shelf offerings and the associated prospectus supplements. The platform pairs these filings with AI-powered summaries designed to clarify key terms, highlight significant financing structures, and explain how reported events relate to the company’s commercialization of LYMPHIR and its late-stage pipeline assets Mino-Lok and CITI-002 (Halo-Lido). This makes it easier to understand complex documents such as 8-Ks, S-3 registration statements, and related exhibits without reading every line of legal text.
Citius Pharmaceuticals reported its first product revenue after the December 2025 launch of LYMPHIR through majority-owned Citius Oncology, recording $3.9 million in revenue for the fiscal first quarter ended December 31, 2025. Total revenue was $3,944,111, with a net loss attributable to common stockholders of $8,220,785, or $0.38 per share.
Cash and cash equivalents were $7,721,393 as of December 31, 2025, supported by $20,877,925 in net proceeds from common stock offerings during the quarter. Net cash used in operating activities was $13,008,822, and the company also paid $4,400,000 in license fees.
Citius received a Nasdaq notice that its common stock bid price has stayed below the $1.00 minimum for 30 consecutive business days. The company has 180 days, until August 10, 2026, to regain compliance, with the possibility of an additional 180-day period, and is evaluating options including a potential reverse stock split. The notice has no immediate effect on the Nasdaq Capital Market listing.
Citius Pharmaceuticals reported its first commercial revenue from LYMPHIR in the quarter ended December 31, 2025, generating $3.9M of net revenue and about $3.2M of gross profit. Despite this, the company recorded a net loss of $9.4M and used $13.0M of cash in operating activities, leaving cash and cash equivalents of $7.7M.
Management states that existing cash is expected to fund operations only through May 2026 and that there is “substantial doubt” about the ability to continue as a going concern without additional capital. Citius also received a Nasdaq notice in February 2026 for failing to meet the $1.00 minimum bid price requirement. To support liquidity, Citius and majority‑owned Citius Oncology completed multiple equity and pre‑funded warrant offerings during 2025 and the quarter, significantly increasing shares outstanding and creating a large warrant overhang.
Citius Pharmaceuticals filed an amended annual report to update the non‑financial Part III sections for the year ended September 30, 2025. The amendment adds detailed information on directors and executive officers, compensation, equity plans, related‑party transactions and auditor fees, but does not change previously reported financial results.
The filing describes the current board and management team, their roles and committee assignments, and confirms most directors meet Nasdaq independence standards. It outlines executive pay structures, including salaries, target bonuses and stock‑based incentives, and summarizes employment and severance terms for key executives.
The report shows equity compensation activity and that 839,510 shares are subject to outstanding awards, with 118,000 shares remaining available under the 2023 plan. It discloses insider ownership levels, related‑party warrant term extensions involving senior executives, and audit, audit‑related and tax fees paid to the independent auditor, all of which were pre‑approved by the Audit and Risk Committee.
Citius Pharmaceuticals reported that it posted an updated Corporate Presentation on its website and furnished it as Exhibit 99.1 in an Item 7.01 Regulation FD disclosure. The company noted that this information is not deemed “filed” under Section 18 of the Exchange Act and is not incorporated by reference unless specifically referenced in a future filing.
Citius Pharmaceuticals (CTXR) completed a registered direct offering with an institutional investor, issuing 1,460,000 common shares at $1.51 and pre-funded warrants for up to 2,513,510 shares at $1.5099. The company also issued investor warrants to purchase up to 3,973,510 shares at an exercise price of $1.40, exercisable immediately for five years.
Gross proceeds were approximately $6.0 million, with expected net proceeds of about $5.5 million after fees. Citius plans to use the funds to support the commercial launch of LYMPHIR™, milestone and regulatory payments, development initiatives across its pipeline, and general corporate purposes. H.C. Wainwright acted as placement agent, earning a 7.0% cash fee plus expenses and received placement agent warrants for up to 278,146 shares at a $1.8875 exercise price.
The warrants include a 4.99% (or 9.99% if elected) Beneficial Ownership Limitation and allow cashless exercise if no effective resale registration is available. For 90 days after closing, Citius agreed not to issue additional equity, with an exception permitting “at the market” sales after 30 days at $2.15 or higher.
Citius Pharmaceuticals (CTXR) completed a registered direct offering with an institutional investor, issuing 1,460,000 common shares at $1.51 and pre-funded warrants for up to 2,513,510 shares at $1.5099. The company also issued investor warrants to purchase up to 3,973,510 shares at an exercise price of $1.40, exercisable immediately for five years.
Gross proceeds were approximately $6.0 million, with expected net proceeds of about $5.5 million after fees. Citius plans to use the funds to support the commercial launch of LYMPHIR™, milestone and regulatory payments, development initiatives across its pipeline, and general corporate purposes. H.C. Wainwright acted as placement agent, earning a 7.0% cash fee plus expenses and received placement agent warrants for up to 278,146 shares at a $1.8875 exercise price.
The warrants include a 4.99% (or 9.99% if elected) Beneficial Ownership Limitation and allow cashless exercise if no effective resale registration is available. For 90 days after closing, Citius agreed not to issue additional equity, with an exception permitting “at the market” sales after 30 days at $2.15 or higher.
Citius Pharmaceuticals (CTXR) launched a primary offering of 1,460,000 shares of common stock, Pre-funded Warrants to purchase up to 2,513,510 shares, and Common Warrants to purchase up to 3,973,510 shares, plus Placement Agent Warrants to purchase up to 278,146 shares. The filing also registers up to 6,765,166 shares issuable upon exercise of the warrants.
Securities are sold at $1.51 per share and accompanying Common Warrant and $1.5099 per Pre-funded Warrant; Common Warrants have a $1.40 exercise price and five-year term, and Pre-funded Warrants have a $0.0001 exercise price with no expiry until exercised. Gross proceeds are $5,999,748.75, placement fees are $420,000, and proceeds to the company before expenses are $5,579,748.75; estimated net proceeds are about $5.5 million.
Proceeds will support the planned U.S. launch of LYMPHIR, development of Mino-Lok, Halo-Lido and NoveCite, and general corporate purposes. The securities are placed with a single institutional investor on a reasonable best efforts basis, with closing expected on or about October 21, 2025, subject to customary conditions.
Citius Pharmaceuticals (CTXR) launched a primary offering of 1,460,000 shares of common stock, Pre-funded Warrants to purchase up to 2,513,510 shares, and Common Warrants to purchase up to 3,973,510 shares, plus Placement Agent Warrants to purchase up to 278,146 shares. The filing also registers up to 6,765,166 shares issuable upon exercise of the warrants.
Securities are sold at $1.51 per share and accompanying Common Warrant and $1.5099 per Pre-funded Warrant; Common Warrants have a $1.40 exercise price and five-year term, and Pre-funded Warrants have a $0.0001 exercise price with no expiry until exercised. Gross proceeds are $5,999,748.75, placement fees are $420,000, and proceeds to the company before expenses are $5,579,748.75; estimated net proceeds are about $5.5 million.
Proceeds will support the planned U.S. launch of LYMPHIR, development of Mino-Lok, Halo-Lido and NoveCite, and general corporate purposes. The securities are placed with a single institutional investor on a reasonable best efforts basis, with closing expected on or about October 21, 2025, subject to customary conditions.
Citius Pharmaceuticals (CTXR) director and CEO Leonard L. Mazur reported multiple changes to his holdings on Form 4 dated 08/08/2025. He disposed of 410,214 shares of common stock. Two outstanding warrants were amended: a $28.75 warrant for 125,490 shares had its termination extended from 08/14/2025 to 08/14/2026 (old warrant cancelled and replacement granted), and a $19.25 warrant for 89,388 shares was similarly extended from 09/27/2025 to 09/27/2026. The filing lists multiple outstanding stock options totaling 129,600 shares across various strike prices, all held directly. All share amounts reflect a 1-for-25 reverse split effective 11/22/2024.
Citius Pharmaceuticals (CTXR) director and CEO Leonard L. Mazur reported multiple changes to his holdings on Form 4 dated 08/08/2025. He disposed of 410,214 shares of common stock. Two outstanding warrants were amended: a $28.75 warrant for 125,490 shares had its termination extended from 08/14/2025 to 08/14/2026 (old warrant cancelled and replacement granted), and a $19.25 warrant for 89,388 shares was similarly extended from 09/27/2025 to 09/27/2026. The filing lists multiple outstanding stock options totaling 129,600 shares across various strike prices, all held directly. All share amounts reflect a 1-for-25 reverse split effective 11/22/2024.
Myron Z. Holubiak, Vice Chairman and a director of Citius Pharmaceuticals (CTXR), reported the disposition of 79,690 shares of common stock and amendments to two outstanding warrants on 08/08/2025. The warrant amendments cancelled the prior warrants and granted replacement warrants exercisable into 31,373 and 22,344 shares, each extended by one year.
The filing lists multiple stock options and warrants remaining beneficially owned by the reporting person, including direct options exercisable into a total of 107,667 common shares and warrants covering 53,717 common shares. Certain options are held indirectly by the reporting person’s daughter and are disclaimed. All share amounts reflect the 1-for-25 reverse stock split effective November 22, 2024.
Citius Pharmaceuticals reported that it has issued a press release announcing its results of operations for the third quarter of fiscal 2025. The company states the press release is furnished as Exhibit 99.1 to the Form 8-K and is incorporated by reference into the report. The filing explains that the information in Item 2.02, including Exhibit 99.1, is furnished rather than filed for purposes of the Exchange Act and therefore is not subject to the same liabilities as a filed disclosure.
The Form 8-K lists the furnished exhibit and an interactive cover page document, and it is signed on behalf of the registrant by the chairman and chief executive officer. No financial line items, operating metrics, or forward-looking guidance appear within the 8-K text itself; readers must refer to Exhibit 99.1 for the underlying results.
Citius Pharmaceuticals reported no revenues for the periods presented while preparing for the commercial launch of LYMPHIR, an FDA-approved immunotherapy the company expects to launch in the fourth quarter of 2025. The company had $6.09 million in cash and cash equivalents and $17.21 million of inventory (finished goods and work‑in‑process) at June 30, 2025, and total assets of $127.68 million. For the nine months ended June 30, 2025 the company recorded a net loss of $30.99 million and used $14.67 million of cash in operating activities. Net loss per share for the nine months was $3.27 on a weighted average of 9.02 million shares.
Liquidity remains a material issue: working capital was negative roughly $27.2 million at June 30, 2025 and management states available cash is expected to fund operations only through September 2025, creating substantial doubt about the company’s ability to continue as a going concern. Significant near‑term obligations include a $28.4 million license payable and an outstanding Milestone balance to Dr. Reddy’s of $22.5 million (partially deferred by agreement). The company raised net financing proceeds of approximately $16.5 million during the period, entered distribution arrangements to support LYMPHIR commercialization, and subsequently regained Nasdaq compliance.